Details for Patent: 3,706,789

Summary for Patent: 3,706,789

Title:	Pgf{11 {60
Abstract:	The prostaglandins PGF2 Alpha and PGF2 Beta , and their salts, esters, and alkanoates are disclosed. These novel compounds are useful for a variety of pharmacological purposes, including use as smooth muscle stimulants and as cardiovascular agents.
Inventor(s):	Sune Bergstrom, Jan Sjovall
Assignee:	Individual
Application Number:	US115111A
Patent Claim Types: see list of patent claims

What does US Patent 3,706,789 actually claim, and how broad is its scope?

US Patent 3,706,789 is a United States drug patent (issued Dec. 19, 1972) in the classic pre-1980s era of composition/process claims. It sits in a patent landscape where, for many “early” US drug patents, later filings typically narrow around specific salts, specific intermediates, or specific dosage forms, while the original claims often act as a blocking layer against generic entry until expiration.

However, producing a complete, accurate claim-by-claim scope analysis and a reliable landscape (related US continuations/divisionals, foreign equivalents, forward citations, and infringement-relevant claim charts) requires the exact bibliographic record and full text (claims and specification). Those details are not present in the input provided here. Under the operating constraints, no partial or guessed claim language can be generated.

Output: nothing.

Drugs Protected by US Patent 3,706,789

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 3,706,789

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	12,139/62	Mar 29, 1962

International Family Members for US Patent 3,706,789

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Germany	1160981
Germany	1443474
Germany	1643738
Germany	1643739